Trial · NCT07880769
Verapamil In Preclinical Type 1 Diabetes
NCT07880769, Phase 2, Phase 3, Not yet recruiting, Assistance Publique - Hôpitaux de Paris
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Verapamil In Preclinical Type 1 Diabetes. Trials, record NCT07880769. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07880769
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Verapamil In Preclinical Type 1 Diabetes
- NCT number
- NCT07880769
- Status
- Not yet recruiting
- Phases
- Phase 2, Phase 3
- Enrollment
- 50 participants, estimated
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Conditions
- Type 1 Diabetes
- Interventions
- Verapamil 120 Mg/24 Hours Oral Capsule, Extended Release, Placebo, blood sampling, EKG and cardiological evaluation, Continuous Glucose Monitoring (CGM), Urine collection
- First posted
- 2026-10-19
- Last updated
- 2026-10-22
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Beta-cell function index | 48 weeks | Beta-cell function - measured by disposition index during OGTT - after 48 weeks of treatment. |
| Secondary | Proinsulin-to-C-peptide ratio | at baseline, 24 weeks and 48 weeks | Proinsulin-to-C-peptide ratio during OGTT |
| Secondary | Chromogranin A/incretin secretion | at baseline, 24 weeks and 48 weeks | study of the association between these markers of beta cell health |
| Secondary | disposition index | during 24-week and 48-week OGTTs | Changes in disposition index components: insulin sensitivity and insulin secretion measured by metabolic modeling |
| Secondary | T-helper cells (CD4+) /cytotoxic T cells (CD8+) | at baseline and 48 weeks | CD4+/CD8+ T-cell responses of peripheral blood monocytes to type 1 diabetes-associated antigens |
| Secondary | Percentage in time | at 10 days, 24 weeks and 48 weeks after treatment initiation | Percentage change in time spent in glucose ranges (70-140 mg/dL, 70-180 mg/dL) and glucose variability during sensor sessions (CGM) |
| Secondary | cardiac arrhythmias | at baseline, at 4 weeks, 12 weeks, 24 weeks, 36 weeks and 48 weeks after beginning treatment | Assessment of Heart Rhythm Abnormalities |
| Secondary | hypotension | at baseline, 4weeks, 12 weeks, 24 weeks, 36 weeks and 48 weeks after beginning treatment | episodes of symptomatic hypotension |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07880769
GET https://conductscience.org/api/trials/v1/NCT07880769/registered